Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: A retrospective analysis

Dermatologic Therapy

Volumn 23, Issue 2, 2010, Pages 199-202

  Vena, Gino ^a   Loconsole, Francesco ^a   Mastrandrea, Valentina ^a   Buquicchio, Rosalba ^a   Cassano, Nicoletta ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Dose escalation; Infliximab; Maintenance therapy; Psoriasis; Re induction; Relapse

Indexed keywords

INFLIXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RELAPSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77950111401     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01315.x     Document Type: Article

References (11)

1. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006 : 23 : 451 463.
2. Cassano N, Puglisi Guerra A, Malara C, et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol 2007 : 20 : 647 650.
3. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006 : 33 : 31 36.
4. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005 : 313 : 578 585.
5. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 : 366 : 1367 1374.
6. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007 : 66 : 1233 1238.
7. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007 : 46 : 529 532.
8. van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007 : 36 : 418 423.
9. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 : 26 : 1509 1520.
10. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009 : 104 : 760 767.
11. ® Product Information. European Public Assessment Report, Revision 25, Published November 03, 2009.